January 2014

Omeros reports positive results from OMS824 phase IIa clinical trial

Friday, January 31, 2014

Omeros has announced positive results from a phase IIa clinical trial of OMS824, the company’s phosphodiesterase 10 (PDE10) inhibitor, in which the drug was well-tolerated and demonstrated comparable systemic pharmacokinetics when administered alone and concomitantly with approved antipsychotic agents in patients with schizophrenia. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington’s disease.

[Read More]

Singapore’s influenza vaccines shows favorable immunogenicity, tolerability

Friday, January 31, 2014

Singapore’s Agency for Science, Technology and Research (A*STAR) and Switzerland’s Cytos Biotechnology have announced that their influenza vaccine (gH1-Qbeta) met its primary end point for immunogenicity (seroconversion based on haemaglutination inhibition titres according to FDA criteria) in the phase I clinical trial in healthy Asian volunteers. The induced immune response showed good cross-reactivity to recent drifted H1N1 strains. The H1N1 influenza vaccine candidate is based on Cytos’ proprietary bacteriophage Qbeta virus-like particle (VLP) technology.

[Read More]

MJFF highlights promising Parkinson’s research

Friday, January 31, 2014

Research projects from three biopharmaceutical companies in the U.S. comprise the 2013 second half (2H 2013) of The Michael J. Fox Foundation for Parkinson’s Research (MJFF) Partnering Program. Among the most promising in the MJFF portfolio, Partnering Program participants’ research projects are presented directly to industry groups who may wish to invest in further development of the project. By connecting industry leaders with those studies ripe for investment, the foundation aims to drive forward promising research in Parkinson’s disease (PD) through the pipeline of drug development and eventually into patients’ hands.

[Read More]

Astrazeneca to close India R&D site

Friday, January 31, 2014

AstraZeneca plans to close its Avishkar R&D site in Bangalore later this year, part of the company’s broader global business strategy to simplify its R&D footprint and focus resources on three core therapy areas: oncology; cardiovascular and metabolic diseases; and respiratory, inflammation and autoimmunity.

[Read More]

Bina Technologies expands scientific advisory board and commercial team

Friday, January 31, 2014

Bina Technologies, the genomic big data science company accelerating personalized medicine, has expanded its advisory board and commercial team. This announcement marks the latest in the company’s initiatives to significantly improve genomics data analysis workflows used in clinical research. Bina has expanded its scientific advisory board (SAB), adding four luminaries with experience in clinical genomics research. The company also has brought on two commercial team leaders, tapping into their combined 40+ years of experience driving revolutionary technologies into the genomics market.

[Read More]

Bristol-Myers Squibb names three research project winners for in viral diseases

Friday, January 31, 2014

Three European virology researchers were awarded research grants this week based on their proposed research projects to investigate novel ways to cure viral diseases. The award-winners were chosen by an independent faculty as part of the Partnering for Cure Program, a first-of-its kind, Europe-wide initiative. The program, sponsored by Bristol-Myers Squibb, is designed to accelerate innovative scientific research that could lead to cure in viral diseases, namely HIV, hepatitis B (HBV) and hepatitis C (HCV).

[Read More]